Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + lidocaine hydrochloride
- Development stage
- Unknown
- Lead developer
- Eugia Pharma Specialities
- Modality
- Small Molecules
- Administration
- Parenteral, Topical, Percutaneous
01
Overview
**bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + lidocaine hydrochloride** is a marketed procedural combination kit for local and regional anesthesia, sold as **Point of Care LM 2.2**. The therapeutic components are **lidocaine hydrochloride** and **bupivacaine hydrochloride**, both amide-type local anesthetics that reduce nerve conduction by reversibly blocking voltage-gated sodium channels; **isopropyl alcohol** and **povidone-iodine** function as antiseptic skin-preparation components packaged with the anesthetics for point-of-care use. Public labeling identifies the kit on DailyMed, and the included bupivacaine component is used for local or regional anesthesia or analgesia in surgical, diagnostic, therapeutic, dental/oral, and obstetrical procedures. The product is associated with AuroMedics and represents a combination kit of established generic agents rather than a novel single active pharmaceutical entity.
- Brand names
- Point of Care LM 2.2
- Other names
- bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + lidocaine hydrochloridelidocaine hydrochloride + bupivacaine hydrochloride + isopropyl alcohol + povidone-iodinePoint of Care LM 2.2 anesthetic kit
02
Targets
NaV (Voltage-gated sodium channels)Kir (Inward-rectifier potassium channels)
Beyond the preview
Go deeper on bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + lidocaine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + lidocaine hydrochloride.